



October 1, 2025

BSE Limited
Floor 25, P. J. Towers Dalal
Street, Fort,
Mumbai - 400 001

Scrip Code: **530019**

National Stock Exchange of India Limited
Exchange Plaza
Bandra Kurla Complex, Bandra (E),
Mumbai - 400 051

Symbol: **JUBLPHARMA**

Sub.: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations")

Dear Sirs,

Pursuant to Regulation 30 of the SEBI Listing Regulations, and in continuation of our earlier communication dated June 12, 2025 and September 1, 2025, we wish to inform you that the Board of Directors of Jubilant Biosys Limited (JBL), a wholly-owned subsidiary of the Company had today, i.e. on October 1, 2025, approved the allotment of 5,15,59,030 Optionally Convertible Redeemable Non-Cumulative Preference Shares (OCRPS), each having a face value of ₹10 and issued at ₹100 per share (including a premium of ₹90), amounting to a total of ₹5,15,59,03,000. This allotment was made as part of the consideration for acquiring the Active Pharmaceutical Ingredients (API) business from JBL on a slump sale basis. The remaining ₹80,00,00,000 of the consideration was paid in cash, in accordance with the terms of the Business Transfer Agreement executed between JBL and the Company on June 12, 2025.

The above mentioned document will be simultaneously posted on the Company's website at www.jubilantpharmova.com.

Date and time of event – October 1, 2025; 12:36 pm (IST).

You are requested to kindly take the same on record.

Thanking you,

Yours faithfully,

For Jubilant Pharmova Limited

Naresh Kapoor
Company Secretary

A Jubilant Bhartia Company

OUR VALUES



Jubilant Pharmova Limited

1-A, Sector 16-A,
Noida-201 301, UP, India
Tel: +91 120 4361000
Fax: +91 120 4234895-96
www.jubilantpharmova.com

Regd Office:

Bhartiagram, Gajraula
Distt. Amroha - 244 223
UP, India

CIN : L24116UP1978PLC004624